NDAIMPLANTATIONIMPLANT
Approved
Dec 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
ZOLADEX (goserelin) by TerSera Therapeutics. Approved for prostate cancer, breast cancer, ovarian cancer. First approved in 1995.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZOLADEX (goserelin) is a GnRH agonist implant administered subcutaneously for hormone-responsive cancers including prostate, breast, and ovarian cancer, as well as spinobulbar muscular atrophy. It works by suppressing luteinizing hormone and follicle-stimulating hormone, reducing testosterone and estrogen levels to inhibit cancer cell growth. The drug has been a foundational endocrine therapy option since 1995.
$0.711MPart D
LOE ApproachingDeclining product in LOE-approaching phase signals reduced team expansion and shift toward retention and efficiency roles rather than growth hiring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (3)
Worked on ZOLADEX at TerSera Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.